Astria Therapeutics Inc • ATXS

Capital at risk.

About Astria Therapeutics Inc
Ticker
info
ATXS
Trading on
info
NASDAQ
ISIN
info
US04635X1028
Industry
info
Biotechnology
Sector
info
Healthcare
CEO
info
Jill C. Milne Ph.D.
Headquarters
info
75 State Street, Boston, MA, United States, 02109
Employees
info
59
Website
info
astriatx.com
Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema. The company is also developing STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, an immune disorder associated with loss of skin barrier function and itching. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is headquartered in Boston, Massachusetts.
Metrics
BasicAdvanced
Market cap
info
$352M
P/E ratio
info
-
EPS
info
-$2.18
Dividend Yield
info
0.00%
Beta
info
0.69
Forward P/E ratio
info
0
EBIDTA
info
$-32.4M
Ex dividend date
info
-
Price & volume
Market cap
info
$352M
Average daily volume
info
0.2M
90-day return
info
-
30-day return
info
-
7-day return
info
-
Dividends
Dividend per share
info
$0.00
Dividend yield
info
0.00%
Forward dividend per share
info
$0.00
Forward dividend yield
info
0.00%
Payout ratio
info
0.00%
Valuation
P/E ratio
info
0
Forward P/E
info
0
PEG ratio
info
-
Trailing P/E
info
0
Price to sales
info
0
Price to book
info
1.43
Earnings
EPS
info
-$2.18
EPS estimate (current quarter)
info
-$0.42
EPS estimate (next quarter)
info
-$0.43
EBITDA
info
$-32.4M
Revenues (TTM)
info
$0M
Revenues per share (TTM)
info
$0.00
Technicals
Beta
info
0.69
52-week High
info
$16.90
52-week Low
info
$5.84
50-day moving average
info
$7.69
200-day moving average
info
$9.88
Short ratio
info
10.38
Short %
info
5.65%
Management effectiveness
ROE (TTM)
info
38.03%
ROA (TTM)
info
22.72%
Profit margin
info
0.00%
Gross profit margin
info
$0M
Operating margin
info
0.00%
Growth
Quarterly earnings growth (YoY)
info
0.00%
Quarterly revenue growth (YoY)
info
0.00%
Share stats
Outstanding Shares
info
56.4M
Float
info
31.1M
Insiders %
info
0.61%
Institutions %
info
104.56%
Analyst Insights & forecasts
info

100% Buy

0% Hold

0% Sell

Based on information from 7 analysts.

Average price target

info
$26.50
Earnings per share (EPS) forecast
windowbar_chart_4_bars
Actual
info
Expected
info
Surprise
info
-$0.94
-$0.78
20.51%
Q4 • 23Beat
-$0.38
-$0.36
5.56%
Q1 • 24Beat
-$0.43
-$0.38
13.16%
Q2 • 24Beat
-$0.42
-$0.42
-
Q3 • 24Beat
-
-
-
Q4 • 24Current
QuarterlyAnnual
Financial Performance
windowbar_chart_4_bars
Income StatementBalance SheetCash Flow
windowbar_chart_4_bars
Revenue
info
Net income
info
Profit margin
info
$0M
$-24.2M
∞%
Q2 • 24
$0M
$-24.5M
∞%
Q3 • 24
NaN%
1.50%
NaN%
QoQ growth
QuarterlyAnnual
Totals assets
info
Total liabilities
info
Debt to assets
info
$368M
$20.9M
5.68%
Q2 • 24
$362M
$20M
5.53%
Q3 • 24
1.73%
4.43%
2.75%
QoQ growth
QuarterlyAnnual
Operating
info
Investing
info
Financing
info
Free cash flow
info
$-16.8M
$-68.1M
$0.1M
$-17.1M
Q2 • 24
$-28M
$6.2M
$15.3M
$-28M
Q3 • 24
66.55%
109.09%
16,177.66%
63.69%
QoQ growth
QuarterlyAnnual
Sentiment analysis

-1.5

Neutral

+1.5

0.25

Last 30 days

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

How much is a Astria Therapeutics Inc share?
Collapse

Astria Therapeutics Inc shares are currently traded for undefined per share.

How many shares does Astria Therapeutics Inc have?
Collapse

Astria Therapeutics Inc currently has 56.4M shares.

Does Astria Therapeutics Inc pay dividends?
Collapse

No, Astria Therapeutics Inc doesn't pay dividends.

What is Astria Therapeutics Inc 52 week high?
Collapse

Astria Therapeutics Inc 52 week high is $16.90.

What is Astria Therapeutics Inc 52 week low?
Collapse

Astria Therapeutics Inc 52 week low is $5.84.

What is the 200-day moving average of Astria Therapeutics Inc?
Collapse

Astria Therapeutics Inc 200-day moving average is $9.88.

Who is Astria Therapeutics Inc CEO?
Collapse

The CEO of Astria Therapeutics Inc is Jill C. Milne Ph.D..

How many employees Astria Therapeutics Inc has?
Collapse

Astria Therapeutics Inc has 59 employees.

What is the market cap of Astria Therapeutics Inc?
Collapse

The market cap of Astria Therapeutics Inc is $352M.

What is the P/E of Astria Therapeutics Inc?
Collapse

The current P/E of Astria Therapeutics Inc is null.

What is the EPS of Astria Therapeutics Inc?
Collapse

The EPS of Astria Therapeutics Inc is -$2.18.

What is the PEG Ratio of Astria Therapeutics Inc?
Collapse

The PEG Ratio of Astria Therapeutics Inc is null.

What do analysts say about Astria Therapeutics Inc?
Collapse

According to the analysts Astria Therapeutics Inc is considered a buy.